Aakash Desai: Efficacy, Innovation and Cost of FDA-Approved NSCLC Drugs

Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn:

“We’re excited to share our poster from ESMO24 on the ‘Efficacy, Innovation and Cost of FDA-Approved NSCLC Drugs’, co-authored with Daniel Michaeli and team.

Key Insights:

• 64% of FDA-approved drugs for NSCLC have biomarker-based targets like EGFR, ALK, and PD-L1.
•  The average time from IND to FDA approval is 1.8 years shorter for NSCLC drugs.
• Drugs with biomarkers demonstrated significantly greater overall survival (OS) and progression-free survival (PFS).
• Median monthly cost for NSCLC treatments is $18,822, with biomarker-based therapies often priced higher.

These findings highlight the balance between innovation and cost in lung cancer treatment. Let’s continue working towards more effective and accessible options for patients!”

Source: Aakash Desai/LinkedIn